Literature DB >> 8780719

Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer.

W Miwa1, J Yasuda, Y Murakami, K Yashima, K Sugano, T Sekine, A Kono, S Egawa, K Yamaguchi, Y Hayashizaki, T Sekiya.   

Abstract

In the human pancreatic cancer cell line PANC1, we detected several DNA fragments with abnormally intensified signals by restriction landmark genomic scanning. Major five of these fragments were cloned. All of the cloned fragments were mapped at the 19q13.1-13.2 region where the AKT2 oncogene was located. Southern blotting using the cloned DNA fragments and a fragment of AKT2 cDNA as probes revealed that the AKT2 gene was amplified in 3 of 12 pancreatic cancer cell lines analyzed including PANC1 and in 3 of 20 primary pancreatic cancers. The AKT2 gene was overexpressed in the 3 cell lines with the amplified gene. The results suggest that the AKT2 gene is a candidate oncogene activated by amplification in some human pancreatic cancers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8780719     DOI: 10.1006/bbrc.1996.1280

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

1.  The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis.

Authors:  K Jiang; D Coppola; N C Crespo; S V Nicosia; A D Hamilton; S M Sebti; J Q Cheng
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

2.  Akt kinase mediates the prosurvival effect of smoking compounds in pancreatic ductal cells.

Authors:  Chang-Hwan Park; In-Seok Lee; Paul Grippo; Stephen J Pandol; Anna S Gukovskaya; Mouad Edderkaoui
Journal:  Pancreas       Date:  2013-05       Impact factor: 3.327

Review 3.  The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells.

Authors:  M R Moniri; L-J Dai; G L Warnock
Journal:  Cancer Gene Ther       Date:  2014-01-03       Impact factor: 5.987

Review 4.  Diverse mechanisms of AKT pathway activation in human malignancy.

Authors:  Mitchell Cheung; Joseph R Testa
Journal:  Curr Cancer Drug Targets       Date:  2013-03       Impact factor: 3.428

5.  Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo.

Authors:  Yan Shi; Xuesong Liu; Edward K Han; Ran Guan; Alexander R Shoemaker; Anatol Oleksijew; Keith W Woods; John P Fisher; Vered Klinghofer; Loren Lasko; Thomas McGonigal; Qun Li; Saul H Rosenberg; Vincent L Giranda; Yan Luo
Journal:  Neoplasia       Date:  2005-11       Impact factor: 5.715

6.  Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation.

Authors:  Andreas G Bader; Peter K Vogt
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 7.  Pancreatic carcinogenesis.

Authors:  Jan-Bart M Koorstra; Steven R Hustinx; G Johan A Offerhaus; Anirban Maitra
Journal:  Pancreatology       Date:  2008-04-01       Impact factor: 3.996

8.  Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells.

Authors:  Jan N Kreutzer; Maria Ruzzene; Barbara Guerra
Journal:  BMC Cancer       Date:  2010-08-19       Impact factor: 4.430

9.  Phenanthrene-based tylophorine-1 (PBT-1) inhibits lung cancer cell growth through the Akt and NF-kappaB pathways.

Authors:  Jau-Chen Lin; Shuenn-Chen Yang; Tse-Ming Hong; Sung-Liang Yu; Qian Shi; Linyi Wei; Hsuan-Yu Chen; Pan-Chyr Yang; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

10.  Akt1 governs breast cancer progression in vivo.

Authors:  Xiaoming Ju; Sanjay Katiyar; Chenguang Wang; Manran Liu; Xuanmao Jiao; Shengwen Li; Jie Zhou; Jacob Turner; Michael P Lisanti; Robert G Russell; Susette C Mueller; John Ojeifo; William S Chen; Nissim Hay; Richard G Pestell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.